The U.S. Attorney’s Office for the District of Colorado has opened a grand jury investigation into DaVita, a Denver-based kidney-dialysis firm, according to a Denver Post report.
Kent Thiry, CEO of DaVita, said the investigation is in its preliminary stages. He also said this investigation overlaps with a 2005 investigation by the U.S. Attorney’s Office in Missouri looking into allegations that DaVita overused Epogen and billed the government for it. Mr. Thiry said prosecutors in Colorado are particularly interested in the firm’s relationships with physicians.
“We do thousands of transactions, including hundreds with physicians, and we work hard to get every one right,” Thiry said in the report. “We are comfortable and confident in our business practices.”
A spokesperson for the U.S. Attorney’s Office in Colorado declined to comment on the investigation, according to the report.
Read the Denver Post report on the investigation into DaVita.
Related Articles on Healthcare Fraud:
UCB Pleads Guilty to Off-Label Marketing of Epilepsy Drug; Will Pay $34M
Novo Nordisk Agrees to Pay $1.7M to Settle Kickback Allegations
Whistleblowers Claim DaVita Wasted Drugs to Overbill Medicare
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
